"Data Leak Boosts LEGN Stock and J&J's Carvykti"
TL;DR
Legend Biotech's stock surged 19.6% after reportedly positive test results for its blood cancer drug Carvykti, which led to a 74% reduction in the risk of relapse in the Phase 3 study called Cartitude-4. The drug could be the best in its CAR-T class for treating multiple myeloma, according to RBC Capital Markets analyst Leonid Timashev. The results offer a potential $9.6 billion treatment opportunity not fully reflected in LEGN stock.
Topics:businessbiotech#biotech#car-t-drugs#carvykti#johnson-and-johnson#legend-biotech#multiple-myeloma
- LEGN Stock Breaks Out; Leaked Documents Show Promise In $9.6 Billion Market | Investor's Business Daily Investor's Business Daily
- Leaked abstract shows massive benefit for J&J, Legend's Carvykti FiercePharma
- Why Shares of Legend Biotech Jumped Wednesday The Motley Fool
- Data Leak Shows J&J’s and Legend’s Carvykti Exceeds Expectations BioSpace
Want the full story? Read the original reporting
Read on Investor's Business Daily